JP2020524696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524696A5 JP2020524696A5 JP2019570986A JP2019570986A JP2020524696A5 JP 2020524696 A5 JP2020524696 A5 JP 2020524696A5 JP 2019570986 A JP2019570986 A JP 2019570986A JP 2019570986 A JP2019570986 A JP 2019570986A JP 2020524696 A5 JP2020524696 A5 JP 2020524696A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- binding
- antigen
- use according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100031506 Complement C5 Human genes 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 13
- 208000002874 Acne Vulgaris Diseases 0.000 claims 10
- 206010000496 acne Diseases 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 206010000269 abscess Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 210000000440 neutrophil Anatomy 0.000 claims 8
- 210000000106 sweat gland Anatomy 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 208000011580 syndromic disease Diseases 0.000 claims 7
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 6
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 claims 6
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 claims 6
- 208000010265 Sweet syndrome Diseases 0.000 claims 6
- 206010053555 Arthritis bacterial Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 208000017520 skin disease Diseases 0.000 claims 5
- 206010048768 Dermatosis Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 3
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- YOKBGCTZYPOSQM-HPSWDUTRSA-N (2s)-2-acetamido-n-[(3s,9s,12s,15r,18s)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1h-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide Chemical compound C([C@H](NC(=O)C)C(=O)N[C@@H]1C(N2CCC[C@H]2C(=O)N[C@H](CC2CCCCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC1)=O)C1=CC=CC=C1 YOKBGCTZYPOSQM-HPSWDUTRSA-N 0.000 claims 2
- 108010048280 AcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg) Proteins 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 208000002557 hidradenitis Diseases 0.000 claims 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000002956 necrotizing effect Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000000552 rheumatic effect Effects 0.000 claims 2
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 102100032996 C5a anaphylatoxin chemotactic receptor 2 Human genes 0.000 claims 1
- 102000003712 Complement factor B Human genes 0.000 claims 1
- 108090000056 Complement factor B Proteins 0.000 claims 1
- 108091008102 DNA aptamers Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 101000868001 Homo sapiens C5a anaphylatoxin chemotactic receptor 2 Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17177657.8 | 2017-06-23 | ||
| EP17177657 | 2017-06-23 | ||
| EP17189938 | 2017-09-07 | ||
| EP17189938.8 | 2017-09-07 | ||
| PCT/EP2018/065676 WO2018234118A1 (en) | 2017-06-23 | 2018-06-13 | Treatment of inflammatory diseases with inhibitors of c5a activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524696A JP2020524696A (ja) | 2020-08-20 |
| JP2020524696A5 true JP2020524696A5 (enExample) | 2021-07-26 |
| JP7502865B2 JP7502865B2 (ja) | 2024-06-19 |
Family
ID=62636193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570986A Active JP7502865B2 (ja) | 2017-06-23 | 2018-06-13 | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3642230A1 (enExample) |
| JP (1) | JP7502865B2 (enExample) |
| KR (1) | KR20200020727A (enExample) |
| CN (1) | CN111201241A (enExample) |
| AU (1) | AU2018286754A1 (enExample) |
| CA (1) | CA3066689C (enExample) |
| IL (1) | IL271074A (enExample) |
| SG (1) | SG11201912882QA (enExample) |
| TW (1) | TWI786132B (enExample) |
| WO (1) | WO2018234118A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| JP7617012B2 (ja) | 2019-03-14 | 2025-01-17 | モルフォシス・アーゲー | Ｃ５ａＲを標的とする抗体 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| AU2020438234A1 (en) * | 2020-03-27 | 2022-09-29 | Inflarx Gmbh | Inhibitors of C5a for the treatment of corona virus infection |
| EP4172200A4 (en) * | 2020-06-24 | 2024-10-30 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | ANTIBODIES SPECIFICALLY RECOGNIZING C5A AND THEIR USES |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AUPR833401A0 (en) | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| PL3385384T3 (pl) | 2004-02-12 | 2021-03-08 | Archemix Llc | Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem |
| WO2005092366A1 (en) * | 2004-03-26 | 2005-10-06 | Promics Pty Limited | TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS |
| US20110301098A1 (en) | 2006-07-21 | 2011-12-08 | Quax Paul H A | Treatment for intimal hyperplasia and related conditions |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| ES2577548T3 (es) | 2008-12-22 | 2016-07-15 | Chemocentryx, Inc. | Antagonistas de C5aR |
| GB0905790D0 (en) | 2009-04-03 | 2009-05-20 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| US9126939B2 (en) | 2010-06-24 | 2015-09-08 | Pingchen Fan | C5AR antagonists |
| PL2970974T3 (pl) | 2013-03-14 | 2018-01-31 | Alnylam Pharmaceuticals Inc | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania |
| DK2994488T3 (da) * | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| EP3119802B1 (en) | 2014-03-20 | 2019-12-04 | InflaRx GmbH | Inhibitors of c5a for the treatment of viral pneumonia |
| EP3194596A1 (en) | 2014-09-16 | 2017-07-26 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| JP6479974B2 (ja) | 2014-10-15 | 2019-03-06 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 大規模エクリズマブ産生細胞培養を再現する方法 |
| FR3030515B1 (fr) * | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| US20180142010A1 (en) | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
| PL3411400T3 (pl) | 2017-04-03 | 2021-12-20 | Inflarx Gmbh | Leczenie chorób zapalnych za pomocą inhibitorów aktywności c5a |
-
2018
- 2018-06-13 JP JP2019570986A patent/JP7502865B2/ja active Active
- 2018-06-13 AU AU2018286754A patent/AU2018286754A1/en not_active Abandoned
- 2018-06-13 CA CA3066689A patent/CA3066689C/en active Active
- 2018-06-13 SG SG11201912882QA patent/SG11201912882QA/en unknown
- 2018-06-13 TW TW107120362A patent/TWI786132B/zh active
- 2018-06-13 CN CN201880041303.4A patent/CN111201241A/zh active Pending
- 2018-06-13 WO PCT/EP2018/065676 patent/WO2018234118A1/en not_active Ceased
- 2018-06-13 EP EP18732016.3A patent/EP3642230A1/en active Pending
- 2018-06-13 KR KR1020197038211A patent/KR20200020727A/ko not_active Ceased
-
2019
- 2019-12-01 IL IL271074A patent/IL271074A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515643A5 (enExample) | ||
| JP2020524696A5 (enExample) | ||
| Ni et al. | An impaired intrinsic microglial clock system induces neuroinflammatory alterations in the early stage of amyloid precursor protein knock-in mouse brain | |
| Singh et al. | Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis | |
| Izuhara et al. | Recent developments regarding periostin in bronchial asthma | |
| US20210386855A1 (en) | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist | |
| US20240156913A1 (en) | Treatment and prevention of metabolic diseases | |
| JP2022521591A (ja) | 腎障害の治療 | |
| JP2010505878A (ja) | 線維症の処置のためのｃｃｒ２アンタゴニスト | |
| JP2023113725A (ja) | 平滑筋細胞媒介性疾患の治療 | |
| JP2017537973A5 (enExample) | ||
| JP2008532493A (ja) | Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析 | |
| WO2013144563A1 (en) | Treatment of acute inflammation in the respiratory tract | |
| Zheng et al. | Pivotal role of cerebral interleukin-23 during immunologic injury in delayed cerebral ischemia in mice | |
| CN102307899A (zh) | 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂 | |
| CN114651010A (zh) | 类风湿性关节炎的诊断和治疗方法 | |
| De Corso et al. | Thymic Stromal Lymphopoietin (TSLP): evidence in respiratory epithelial-driven diseases including chronic rhinosinusitis with nasal polyps | |
| Anderson | Advances in understanding COPD | |
| JP2024512384A (ja) | 汎発型膿疱性乾癬における抗ｉｌ－３６ｒ抗体による処置に関連したバイオマーカー | |
| Li et al. | Intranasal delivery of E-selectin reduces atherosclerosis in ApoE−/− mice | |
| WO2015187704A1 (en) | Dgat1 inhibition for treatment of demyelinating inflammatory disease | |
| Drygała et al. | A summary of novel biologics for asthma treatment | |
| WO2023021006A1 (en) | Il-1 targeting agents for treatment of pitiyriasis rubra pilaris | |
| JP7325799B2 (ja) | 神経新生の低下抑制剤 | |
| JPWO2019236528A5 (enExample) |